Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial (Q80688403)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17658393%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

title

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17658393%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

1

Suzanne Oparil

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17658393%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Steven A Yarows

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17658393%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Samir Patel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17658393%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Hui Fang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17658393%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Jack Zhang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17658393%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Andrew Satlin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17658393%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

language of work or name

English

0 references

publication date

1 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17658393%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17658393%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

370

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17658393%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

221-229

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17658393%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

9583

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17658393%20AND%20SRC:MED&resulttype=core&format=json

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Inhibition of renin secretion by angiotensin. II.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Renin inhibition: what are the therapeutic opportunities?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Associati

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Changes in endocrine activities relative to obesity in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961124-6

7 January 2021

10.1016/S0140-6736(07)61124-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17658393%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference